As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Sector: Services-Commercial Physical & Biological Research
Industry: Medical - Diagnostics & Research
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 1.28M shares outstanding
USAs a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer.
Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
James Michael Edwards
Chief Financial Officer
Jamie Platt
Director
Jamie Platt, PhD
Director
John J. Oppenheimer, M.D.
Director
Employees
57
Country
US
Sector
Healthcare
Website
bioaffinitytech.com
Loading congressional disclosures…
based on 1.28M shares outstanding
US30d Avg
3.83M
60d Avg
5.74M
90d Avg
3.74M
